Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 6,064 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Completed Phase 2 Interventional Results available

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

NCT01173471
View directory record Official record
Conditions
Raised Intraocular Pressure
Interventions
AZD4017, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Newport Beach, California • Atlanta, Georgia • Morrow, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 21, 2026, 2:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Breast Cancer Study Tracking Risk Awareness of Alcohol Consumption and Improving Knowledge in Young Adult Women

NCT07320664
View directory record Official record
Conditions
Behavior, Risk
Interventions
Alcohol and Breast Cancer Risk Messages, Skin Cancer Risk Messages
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention

NCT03795116
View directory record Official record
Conditions
Fibrosis, Skin Scarring, Skin Wound, Hypertrophic Scar, Scar, Keloid
Interventions
LED-RL phototherapy, Mock irradiation
Device
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 21, 2026, 2:38 PM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

NCT07756736
View directory record Official record
Conditions
Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
25 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

NCT02272634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
YPL-001 80 mg, YPL-001 160 mg, Placebo
Drug
Lead sponsor
Yungjin Pharm. Co., Ltd.
Industry
Eligibility
30 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Winter Park, Florida • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898
View directory record Official record
Conditions
Covid19
Interventions
BGB-DXP593, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 21, 2026, 2:38 PM EDT
Active, not recruiting No phase listed Observational

A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis

NCT03127709
View directory record Official record
Conditions
Histiocytosis
Interventions
Trail Making Test, Parts A & B, Brief Test of Attention, Symbol Span, Controlled Oral Word Association Test, The Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Hospital Anxiety and Depression Scale, McGill Quality of Life Scale, MR Brain Imaging, Resting state functional MRI, Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Completed No phase listed Observational

Hypertension Management Using Remote Patient Monitoring

NCT05562921
View directory record Official record
Conditions
Hypertension
Interventions
Controls-ususal care, Cases-remote patient monitoring prescribed
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 110 Years
Enrollment
1,440 participants
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Multilevel Intervention for Physical Activity in Retirement Communities

NCT01155011
View directory record Official record
Conditions
Physical Activity, Blood Pressure, Physical Functioning, Quality of Life, Sedentary
Interventions
Physical Activity, Group educational sessions, Phone counseling call, Peer Mentoring, Policy Change, Support, Tailored environmental resources, Health check phone call, Pedometer
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
65 Years and older
Enrollment
307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 21, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
lufepirsen high dose, Vehicle, lufepirsen low dose
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
2 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Dothan, Alabama • Petaluma, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

NCT02715193
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Diabetes
Interventions
REMD-477, Placebo Comparator
Biological
Lead sponsor
REMD Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Diego, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

NCT02784106
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Billerica, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants

NCT05436912
View directory record Official record
Conditions
Healthy, Hepatic Impairment
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
7
States / cities
Anaheim, California • Monterey Park, California • Tustin, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

NCT01910571
View directory record Official record
Conditions
Healthy
Interventions
P7435, Placebo
Drug · Other
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

NCT03283371
View directory record Official record
Conditions
Epilepsy, Focal Seizures, Partial Seizures
Interventions
Natalizumab, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 21, 2026, 2:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy

NCT04042298
View directory record Official record
Conditions
Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer, Chemotherapy Effect, 5-Fluorouracil Toxicity
Interventions
Arterial blood pressure, Skin microcirculatory blood flow, Brachial artery blood flow, Venous blood draw
Other
Lead sponsor
Kansas State University
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Study of Urate Elevation in Parkinson's Disease, Phase 3

NCT02642393
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Inosine, Placebo
Drug
Lead sponsor
Michael Alan Schwarzschild
Other
Eligibility
30 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)

NCT03614663
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
ZYN002 - Cannabidiol Transdermal Gel, Placebo Transdermal Gel
Drug · Other
Lead sponsor
Zynerba Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 21, 2026, 2:38 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds

NCT01655407
View directory record Official record
Conditions
Thermal Injury, Deep Partial-Thickness Burn, Full-Thickness Burn
Interventions
Autologous Engineered Skin Substitute, Split-Thickness Autograft (AG)
Drug
Lead sponsor
Amarantus BioScience Holdings, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Pheonix, Arizona • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 21, 2026, 2:38 PM EDT
Active, not recruiting Phase 4 Interventional

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

NCT03953300
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 2:38 PM EDT
Not listed Not applicable Interventional

Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia

NCT05826171
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7
Interventions
High-Intensity Aerobic Exercise Prior to Balance Training, Low-Intensity Exercise Prior to Balance Training
Behavioral
Lead sponsor
Teachers College, Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

NCT02443298
View directory record Official record
Conditions
Asthma
Interventions
placebo, risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Costa Mesa, California • Mountain View, California • Centennial, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

NCT01064414
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Concord, California • Fountain Valley, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 21, 2026, 2:38 PM EDT
Completed Not applicable Interventional

The Impact of Real-World Vibration Feedback Gait Retraining on Gait Biomechanics in People With Chronic Ankle Instability

NCT05327244
View directory record Official record
Conditions
Chronic Ankle Instability
Interventions
Real-world vibration feedback gait retraining
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 21, 2026, 2:38 PM EDT